Calamos Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,122
| Closed | -$567K | – | 948 |
|
|
2024
Q2 | $567K | Sell |
4,122
-2,651
| -39% | -$365K | ﹤0.01% | 666 |
|
|
2024
Q1 | $934K | Buy |
6,773
+338
| +5% | +$46.6K | ﹤0.01% | 627 |
|
|
2023
Q4 | $848K | Buy |
+6,435
| New | +$848K | ﹤0.01% | 646 |
|
|
2023
Q1 | – | Sell |
-13,879
| Closed | -$1.66M | – | 1157 |
|
|
2022
Q4 | $1.66M | Buy |
13,879
+6,492
| +88% | +$775K | 0.01% | 792 |
|
|
2022
Q3 | $785K | Buy |
+7,387
| New | +$785K | ﹤0.01% | 942 |
|
|
2019
Q4 | – | Sell |
-96,622
| Closed | -$8.71M | – | 758 |
|
|
2019
Q3 | $8.71M | Sell |
96,622
-125
| -0.1% | -$11.3K | 0.05% | 350 |
|
|
2019
Q2 | $8.17M | Buy |
+96,747
| New | +$8.17M | 0.05% | 358 |
|